This highly readable first-person story by a writer who suffers from migraine headaches describes new antibody treatments that are under FDA review. The story effectively conveys the risks of trying monoclonal antibodies, describes how they work, and explains hurdles to getting them. Especially effective is a description of the litany of treatment approaches the writer has tried over the years, to little avail, and her quest to participate in clinical trials in pursuit of the “tantalizing reward of a migraine-free life.”
The story is also open about costs and potential harms from the therapies. However, the story could have used more discussion of the evidence for these new therapies–what kind of trials have been conducted, and what are their limitations? What did the trials measure, exactly? Also, the optimistic tone of the headline and lead — which describes their “potential to turn migraine treatment on its head” — doesn’t hint at the cautions further down in the story.
There is clearly a big need for effective new treatments for migraine. This story paints a clear picture of the history of past attempts, accidental discoveries, the range of symptoms that migraines present in different people, and the possibilities, costs, and potential long-term side effects of drugs now being tested.
The story says these treatments could cost “anywhere from $8,000 to $18,000 a year.”
The story didn’t provide any sense of the scope of potential benefits seen in the trials so far. The story says only that “one injection appears to be effective for up to three months with almost no noticeable side effects.” Is this to suggest that everyone in the trials is getting relief for up to three months from one injection? It’s not clear.
Initially the story says patients “report limited side effects that consist mostly of pain at the injection site. Unlike the current preventive medications, there is no nausea, no fuzzy thinking, no nerve pain, no weight loss or gain.”
But it also notes a lack of long-term safety data and “potential long-term effects on blood pressure or other cardiovascular function” as well as potential effects on fertility or placental function.
In the end, the reporter reflects on her own migraines and her own choices: “I think about my two young children and my risk tolerance. Perhaps in ten years I’ll feel differently. For now, however, I pick up the phone and cancel my clinical trial appointment.”
We also like this cautionary sentence: “Right now, the longest patients have been on one of these new therapies is one to two years.”
The story doesn’t give much data on the evidence backing these new treatments, except to say that the longest patients have been on them is “one to two years.” What type of trials have been conducted? How many patients were involved, and how severe or frequent were their headaches? How did the treatments stack up against placebos? Those are just some of the questions that would have been useful to explore. (And if the drug companies aren’t making this information public, that should be clear, too.)
No disease mongering here. The story reports federal data that about 10 percent of men and 20 percent of women in the U.S. reported having a migraine in the last three months, and as many as 2 percent of Americans have at least 15 migraine days every month. “The toll such pain can take on health, morale, and productivity is substantial,” it says.
Two physicians who don’t appear to have interests in promoting these treatments are quoted.
The story gives plenty of details:
A number of people prescribed medications for depression, high blood pressure and epilepsy discovered migraine relief, too. Now, many of those drugs, including propranolol and topiramate, have been tested and approved for migraine. But no one drug works for everyone, and side effects can prove intolerable or downright unpleasant.
The writer also describes her own quest for relief:
Since that day more than 17 years ago, I have tried six preventive prescription medications. Not one helped. I alternated among four different, neurologist-recommended supplements, all to no avail. I received bi-monthly injections of magnesium and participated in one of the first clinical trials of Botox. And while Botox seemed to decrease my migraines by one or two per month, it wasn’t enough to bother fighting about it with a new insurance company. I exercised regularly. I experimented with an elimination diet that left me eating nothing but broccoli and white rice, but still the migraines came. I averaged about 15 to 20 each month.
The story makes it clear these injections aren’t available yet:
Two manufacturers, Amgen (in collaboration with Novartis) and Teva Pharmaceuticals, have completed clinical trials and expect to hear from the FDA by June whether the therapies have been approved. Two more companies, Eli Lilly and Alder Biopharmaceuticals, plan to file for FDA approval later this year.
It also cautions that their high cost means insurance companies might “require patients to have tried just about everything else first.”
The lead states “there isn’t a drug on the market today that prevents (migraines) by targeting the underlying cause.”
This story doesn’t rely on a news release.
Systematic, Criteria-Driven
We will not display your name or e-mail address on the site, nor will we share your e-mail address with any third parties.
Thank you for joining the HealthNewsReview.org mailing list. It’s a good way for you to stay up-to-date on what we’ve published, even if you forget to come to our website every day or every week.
-Gary Schwitzer, Publisher, HealthNewsReview.org
By submitting this form, you are granting: HealthNewsReview.org, University of Minnesota , Minneapolis, MN, 55455, United States, https://www.healthnewsreview.org permission to email you. You may unsubscribe via the link found at the bottom of every email. Emails are serviced by Mailchimp. (See their Email Privacy Policy for details.)
In story on experimental contraceptive gel, Reuters lets drug company control the narrative https://t.co/cKjiNXUfLh
Transparency, accountability, and skill building to fight the corruption of healthcare journalism. A critical function lost. Thank you @garyschwitzer et al for your service to truth, clarity, and ultimately to the Patient Revolution. @patientrev https://t.co/5fKfDwe8bg
Comments
We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.
We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like